Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA-binding agents

Yago Nieto1

  • 1University of Colorado Bone Marrow, Transplant Program, Denver 80262, USA. yago.nieto@uchsc.edu

Cancer Chemotherapy and Biological Response Modifiers
|September 2, 2004
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

British journal of haematology·2026
Same author

A Simplified Frailty Score Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy·2026
Same author

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same author

Recent advances in bispecific natural killer cell engagers for cancer immunotherapy.

Immunotherapy·2026
Same author

NK cell-based immunotherapy.

Human vaccines & immunotherapeutics·2026
Same author

Donor-specific HLA mismatch: haploidentical versus 7/8 mismatched unrelated donor hematopoietic cell transplantation with PTCy.

Bone marrow transplantation·2026
Same journal

Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer chemotherapy and biological response modifiers·2005
Same journal

DNA vaccines for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Cancer chemotherapy and biological response modifiers·2005
Same journal

Current status of interferon-alpha in the treatment of melanoma.

Cancer chemotherapy and biological response modifiers·2005
See all related articles